Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE Guidance - February 2015

The National Institute of Health and Care Excellence (NICE) has published new guidance for the month of February 2015. This month there are three guidelines that impact upon primary care.

The Bladder cancer guideline offers evidence-based advice on the diagnosis and management of bladder cancer in adults.

The Diabetes in pregnancy guideline offers evidence-based advice on managing diabetes and its complications in women who are planning pregnancy and those who are already pregnant. It focuses on areas where additional or different care should be offered to women with diabetes and their newborn babies.

The Irritable bowel syndrome in adults clinical guideline is an update to the original guideline from 2008. It contains advice on the diagnosis and management of irritable bowel syndrome and details the circumstances when people need to be referred to a specialist. Recommendations for ovarian cancer screening as well as dietary and lifestyle advice and pharmacological therapy have been added to and updated.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - February 2015' on Email Share 'NICE Guidance - February 2015' on Delicious Share 'NICE Guidance - February 2015' on Digg Share 'NICE Guidance - February 2015' on Facebook Share 'NICE Guidance - February 2015' on Google+ Share 'NICE Guidance - February 2015' on reddit Share 'NICE Guidance - February 2015' on StumbleUpon Share 'NICE Guidance - February 2015' on Twitter

Drug Safety Update - February 2015

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for February 2015 (PDF). This month there are three updates pertinent to primary care.

The TIOSPIR clinical trial has been published and found no significant difference in mortality when tiotropium is delivered via Respimat or Handihaler device. This is reassuring however patients with certain cardiac conditions were excluded from the trial. As such it is still recommended to take into consideration the risk of cardiovascular side effects in patients with certain cardiovascular conditions including:

  • recent myocardial infarction < 6 months
  • any unstable or life threatening cardiac arrhythmia
  • cardiac arrhythmia requiring intervention or a change in drug therapy in the past year
  • hospitalisation of heart failure (NYHA Class III or IV) within the past year

Clinicians are also reminded that the new drugs and driving offence will be enforced from 2 March 2015 in England and Wales. It is recommended that clinicians talk to patients who are on medicines with potential to impair driving and discuss the patient leaflet advice.

Finally this month there is a summary of letters sent to healthcare professionals since November 2014, including the discontinuation of carbocisteine 125mg/5ml oral solution.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - February 2015' on Email Share 'Drug Safety Update - February 2015' on Delicious Share 'Drug Safety Update - February 2015' on Digg Share 'Drug Safety Update - February 2015' on Facebook Share 'Drug Safety Update - February 2015' on Google+ Share 'Drug Safety Update - February 2015' on reddit Share 'Drug Safety Update - February 2015' on StumbleUpon Share 'Drug Safety Update - February 2015' on Twitter

SMC Update - February 2015

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Colestilan (BindRen®) has been rejected for the treatment of hyperphosphataemia in adult patients with chronic kidney disease (CKD) stage 5 receiving haemodialysis or peritoneal dialysis. Comparative date with others similar agents did not demonstrate non-inferiority conclusively. The manufacturer did not present a sufficiently robust clinical and economic analysis to gain acceptance.

Umeclidinium / Vilanterol (Anoro®) has been accepted for use as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. Two randomised controlled studies demonstrated improved lung function compared with an inhaled long-acting muscarinic antagonist and indirect comparisons demonstrated comparable efficacy with similar drug combinations.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - February 2015' on Email Share 'SMC Update - February 2015' on Delicious Share 'SMC Update - February 2015' on Digg Share 'SMC Update - February 2015' on Facebook Share 'SMC Update - February 2015' on Google+ Share 'SMC Update - February 2015' on reddit Share 'SMC Update - February 2015' on StumbleUpon Share 'SMC Update - February 2015' on Twitter

Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 788,760 spam comments.

atomic-wealth
fond-illness
summer